WALTHAM, Mass. — Thermo Fisher Scientific Inc. has opened a flagship U.S. Bioprocess Design Center at its Plainville, Massachusetts, site, expanding the facility to help customers develop and scale biologic therapies more quickly.
The new center is designed to bring together advanced bioproduction technologies and hands-on collaboration, allowing companies to accelerate process development and move treatments to patients faster. The expansion underscores Thermo Fisher’s strategy to serve as a key innovation partner across the drug development lifecycle.
The Bioprocess Design Center includes 4,000 square feet of laboratory and training space focused on biologics such as vaccines and cell and gene therapies. The site provides access to a full end-to-end bioproduction workflow, including media, cell line development, single-use systems, chromatography, filtration, purification, and analytics, aimed at improving efficiency and reducing time to market.
Onsite specialists offer demonstrations, training, and technical consulting, working directly with customers to refine processes, validate concepts, and address production challenges. The goal is to help companies transition from development to scalable manufacturing more efficiently.
“Our new Bioprocess Design Center brings together Thermo Fisher’s experts and customers to tackle some of the most complex challenges in bioprocessing, demonstrating how collaboration and shared innovation can accelerate therapeutic development and help deliver life-changing therapies to patients faster,” said Daniella Cramp, senior vice president and president, BioProduction and Customer Excellence at Thermo Fisher Scientific. “By creating a space where customers can work side by side with our scientists and engineers, we can help translate innovative ideas into scalable solutions that advance biologics development and manufacturing for customers across the United States.”
Massachusetts officials said the investment reflects the state’s continued strength in the life sciences sector.
“Companies like Thermo Fisher Scientific are choosing Massachusetts because of our world-renowned life sciences sector, and we are proud to partner with them as they continue to grow and invest in our state,” said Governor Maura Healey. “This new Bioprocess Design Center will accelerate cutting-edge research, strengthen our economy, and create new jobs for workers across our state. Massachusetts continues to lead the nation in life sciences because we invest in innovation, support our workforce, and partner with companies that are delivering the next generation of life-saving therapies.”
Thermo Fisher said the center will help customers optimize bioproduction workflows in later stages of drug development, reducing risk and improving scalability as projects move through preclinical work, clinical trials, manufacturing, and commercialization. The company’s Accelerator Drug Development platform provides contract development and manufacturing (CDMO) and contract research (CRO) services across a range of drug types and therapeutic areas.
The addition of the center expands the company’s 290,000-square-foot Plainville facility, which already includes sterile fill-finish and viral vector capabilities. The site is positioned within the broader Massachusetts life sciences ecosystem to support collaboration with customers across the U.S.
“This new Bioprocess Design Center is a strong example of why Massachusetts continues to lead in life sciences,” said Massachusetts Economic Development Secretary Eric Paley. “We are fortunate to have an ecosystem where companies like Thermo Fisher can bring together cutting-edge technology, world-class talent, and close collaboration to move breakthrough therapies from concept to production. Investments like this strengthen our position as a global hub for biomanufacturing and help ensure that the next generation of treatments is developed and delivered faster, right here in Massachusetts.”
